Form SC 13G/A Xenon Pharmaceuticals Filed by: FMR LLC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Xenon Pharmaceuticals (XENE) PT Raised to $56 at RBC Capital
November 13, 2024 6:48 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $56.00 (from $55.00) while maintaining a Outperform rating.
The analyst comments "All remains on track, heading towards a big 2025 for data, with investigator MDD data 1H25 - which we believe... More
